1644 ZXW



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Feldmann and Ravinder N. Maini

Serial No.: 09/754,004 Examiner: P. Gambel

Filed: January 3, 2001 Group Art Unit: 1644

For :  $TNF\alpha$  ANTAGONISTS AND METHOTREXATE IN THE

TREATMENT OF TNF-MEDIATED DISEASE

1185 Avenue of the Americas
New York, New York 10036
February 17, 2005

Commissioner for Patents P.O. Box/1450 Alexandria, VA 22313-1450

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on the attached Form PTO-1449 (EXHIBIT A). Copies of the documents listed below as items 1 and 2 are attached hereto as EXHIBITS 1 and 2:

- St. Clair, E. W., et al., "Combination of Infliximab and Methotrexate Therapy for Early Rheumatoid Arthritis", <u>Arthritis & Rheumatism</u>, 50(11):3432-3443 (2004) (EXHIBIT 1); and
- Klareskog, L., et al., "Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised

Applicants : Marc Feldmann et al.

Serial No. : 09/754,004

: January 3, 2001 Filed

Page 2

controlled trial", The Lancet, 363:675-681 (2004) (EXHIBIT 2).

If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Alan J. Morrison

Reg. No. 37,399

Registration No. 28,678 Alan J. Morrison

John P. White

Registration No. 37,399 Attorneys for Applicant Cooper & Dunham LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400

Form PT	O-144	9 U.S. De	epartment of C	Commerce	Application Number	09/754,004	
			and Tradema		Filing Date	January 3, 2001	
				0.26/	First Named Inventor	Marc Feldmann	
INFORM	IATIC	N DISCLOSURE	CITATION FEB 2 2 2005		Art Unit	1644	
(Use severa	l sheets	if necessary)			Examiner Name	P. Gambel	
				- 2000	Attorney Docket No.	1455/65019-DA	
			137		l	US/JPW/AJM/CY	
ļ		NON I	PATENT LIT	ERAMERE DOC	UMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	, 1					T <sup>2</sup>
		ST. CLAIR, E. W. for Early Rheums (2004)	., et al., "Comb	oination of Inflixi	mab and Methotre		
		KLARESKOG, L., methotrexate comparthritis: double-b (2004)	pared with eac	h treatment alon	e in patients with	n rheumatoid	
							•
			·			2	
				<u> </u>		+	
			-1.2				
-							
EXAMINER SIGNATURE			DATE CONSIDERED				
and not consid	dered. Inc	if citation considered, wheth lude copy of this form with checkmark here if English	next communication	to applicant. <sup>1</sup> Applicant's	P 609: Draw line through a unique citation designation	citation if not in confo on number (optional).	ormance

Applicants: Marc Feldmann et al.

Serial No.: 09/754,004 Filed: January 3, 2001

Exhibit A